UBS Maintains a 'Buy' on Teva Pharma (TEVA); The Decision's In

Article Stock Quotes (3) Comments (0)

UBS maintains a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target of $52.00.

Analyst, Marc Goodman, said the company and investors can breathe a sign of relief as the results have finally come in.

Over the weekend, TEVA reported that U.S. District Court for the Southern District of New York has found in favor of Teva in the Company’s patent infringement lawsuit against Momenta Pharmaceuticals, Inc./Sandoz Inc. (Nasdaq: MNTA) and Mylan Laboratories Inc. (Nasdaq: MYL)/Natco Pharmaceuticals regarding Teva’s relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $38.10 yesterday, with a 52 week range of $35.00-$49.72.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Lazard Capital Downgrades Warner Chilcott (WCRX), Says Deal Could Fall Through
• Lazard Boosts PT on Western Digital (WDC) to $68; Sees Bottoming in HDD
• Goldman Sachs Upgrades Meritor (MTOR) to Buy

Create E-mail Alert Related Categories

Analyst Comments, Litigation

Related Entities

UBS

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?